Tags : antibody-based therapies


Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based

Shots: Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design the other drug candidates Leo will have exclusive, worldwide rights and take care of the development and commercialization of any drugs developed in dermatology. MorphoSys […]Read More